Frontiers in Pharmacology

Multidimensional lipid and inflammatory risk control following evolocumab treatment in real-world ASCVD: a hospital-based cohort study

By Qiang Niu, Xiaolu Liu, Hui Zhang, Qilei Wang, Bo Li

Study in peopleInterventions

The paper

Qiang Niu, Xiaolu Liu, Hui Zhang, Qilei Wang, Bo Li

Central Hospital of Zibo

Frontiers in Pharmacology, 11 Aug 2026

doi.org/10.3389/fphar.2026.1890158 PubMed 42643334

Journal of Clinical Lipidology4 Oct 2026
Estimated sdLDL-C predicts cardiovascular risk in Japanese adults
American Journal of Preventive Cardiology4 Oct 2026
Most US adults meeting PREVENT risk thresholds lack lipid therapy
Journal of Diabetes and Metabolic Disorders4 Oct 2026
Cumulative non-HDL cholesterol is linked to CVD risk
American Journal of Preventive Cardiology4 Oct 2026
Risk factors for atherosclerosis diverge across vascular beds